Study to Evaluate Immunogenicity, Safety, and Tolerability of ZOSTAVAX™ Vaccine (Zoster Vaccine Live, V211) Administered Concomitantly Versus Nonconcomitantly With Quadrivalent Influenza Virus Vaccine (Inactivated) in Participants ≥50 Years of Age (V211-062)
Clinical trial NCT02519855 · COMPLETED
Trial details
- NCT number
- NCT02519855
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2015-09-11
- Primary completion
- 2016-01-26
- Enrollment
- 882
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.